Does OLAPARIB Cause Carcinoembryonic antigen increased? 8 Reports in FDA Database
Prostate Health & Male Vitality — Naturally
ProstaVive: better flow, better sleep, better energy. 180-day guarantee.
According to the FDA Adverse Event Reporting System (FAERS), 8 reports of Carcinoembryonic antigen increased have been filed in association with OLAPARIB (Lynparza). This represents 0.0% of all adverse event reports for OLAPARIB.
8
Reports of Carcinoembryonic antigen increased with OLAPARIB
0.0%
of all OLAPARIB reports
1
Deaths
0
Hospitalizations
How Dangerous Is Carcinoembryonic antigen increased From OLAPARIB?
Of the 8 reports, 1 (12.5%) resulted in death.
Is Carcinoembryonic antigen increased Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for OLAPARIB. However, 8 reports have been filed with the FAERS database.
What Other Side Effects Does OLAPARIB Cause?
Death (4,378)
Malignant neoplasm progression (1,862)
Nausea (1,582)
Anaemia (1,455)
Fatigue (1,437)
Off label use (777)
Vomiting (642)
Drug ineffective (563)
Diarrhoea (514)
Asthenia (491)
What Other Drugs Cause Carcinoembryonic antigen increased?
RIBOCICLIB (143)
LETROZOLE (115)
CAPECITABINE (113)
FULVESTRANT (105)
BEVACIZUMAB (102)
REGORAFENIB (91)
OXALIPLATIN (88)
OSIMERTINIB (82)
PALBOCICLIB (78)
FLUOROURACIL (71)
Which OLAPARIB Alternatives Have Lower Carcinoembryonic antigen increased Risk?
OLAPARIB vs OLARATUMAB
OLAPARIB vs OLECLUMAB
OLAPARIB vs OLIVE OIL\SOYBEAN OIL
OLAPARIB vs OLMESARTAN
OLAPARIB vs OLMESARTAN MEDOXOMIL